This investment will allow the organisation to focus and drive adoption of its NATROX® Oxygen Wound Therapy within the focus countries. Bringing this therapy to the forefront of clinicians’ minds to use when reviewing non-healing wounds is a key commercial strategy.
Craig Kennedy, CEO of Inotec AMD Comments: “The Wealth Club is a forward-thinking Investment group whose investment has given us a fantastic opportunity to further drive clinical adoption of the NATROX® Oxygen Wound Therapy in our key markets. They have been a great group to work with and we are extremely pleased to have them on board”.